Mild Alzheimer's Disease
15
2
2
7
Key Insights
Highlights
Success Rate
70% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
20.0%
3 terminated out of 15 trials
70.0%
-16.5% vs benchmark
7%
1 trials in Phase 3/4
29%
2 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (15)
Low Intensity Focused Ultrasound for Mild Cognitive Impairment and Mild Alzheimer's Disease
A Novel Therapeutic Target for Alzheimer's Disease in Men and Women 50-85 Years of Age.
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-MAPTRx in Patients With Mild Alzheimer's Disease
Deferiprone to Delay Dementia (The 3D Study)
WeArable Neuromodulation DeVice for the TrEatment of Alzheimer's Disease
Lomecel-B Effects on Alzheimer's Disease
pBFS Guided rTMS Treating Mild Alzheimer's Disease(AD)
Medicare Anti-Aβ mAb Coverage With Evidence Development (CED) Study
A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment
Sensory-cognitive and Physical Fitness Training in Mild Cognitive Impairment
Effect of AQW051 in Patients With Memory Impairment
Safety Study of HPP854 in Subjects With Mild Cognitive Impairment or a Diagnosis of Mild Alzheimer's Disease
Early Detection of Mild Cognitive Impairment in Individual Patients
An Escalating Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LNK 754 in Elderly Volunteers and in Subjects With Mild Alzheimer's Disease
Safety and Feasibility of Sodium Oxybate in Mild Alzheimer's Disease Patients